ATE544846T1 - Fusionierte mesenchymale stammzellen zur behandlung von diabetes und verfahren dafür - Google Patents

Fusionierte mesenchymale stammzellen zur behandlung von diabetes und verfahren dafür

Info

Publication number
ATE544846T1
ATE544846T1 AT07861344T AT07861344T ATE544846T1 AT E544846 T1 ATE544846 T1 AT E544846T1 AT 07861344 T AT07861344 T AT 07861344T AT 07861344 T AT07861344 T AT 07861344T AT E544846 T1 ATE544846 T1 AT E544846T1
Authority
AT
Austria
Prior art keywords
methods
fusioned
stem cells
mesenchymal stem
treating diabetes
Prior art date
Application number
AT07861344T
Other languages
English (en)
Inventor
Christof Westenfelder
Original Assignee
Insugen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insugen Llc filed Critical Insugen Llc
Application granted granted Critical
Publication of ATE544846T1 publication Critical patent/ATE544846T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07861344T 2006-09-19 2007-09-19 Fusionierte mesenchymale stammzellen zur behandlung von diabetes und verfahren dafür ATE544846T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84571206P 2006-09-19 2006-09-19
PCT/US2007/020359 WO2008036349A2 (en) 2006-09-19 2007-09-19 Fused stem cells useful for the treatment of diabetes and methods thereof

Publications (1)

Publication Number Publication Date
ATE544846T1 true ATE544846T1 (de) 2012-02-15

Family

ID=39201090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07861344T ATE544846T1 (de) 2006-09-19 2007-09-19 Fusionierte mesenchymale stammzellen zur behandlung von diabetes und verfahren dafür

Country Status (6)

Country Link
US (2) US8119120B2 (de)
EP (1) EP2061874B1 (de)
AT (1) ATE544846T1 (de)
CA (1) CA2693382C (de)
DK (1) DK2061874T3 (de)
WO (1) WO2008036349A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693382C (en) 2006-09-19 2013-09-17 Insugen, Llc Fused stem cells useful for the treatment of diabetes and methods thereof
WO2015058139A1 (en) * 2013-10-18 2015-04-23 Symbiocelltech, Llc Stem cell / islet cell hybrids, generation thereof, and methods for the treatment and cure of insulin-dependent diabetes mellitus
ES2939816T3 (es) * 2015-09-10 2023-04-27 Symbiocelltech Llc Neoislotes que comprenden células madre y de islotes y el tratamiento de la diabetes mellitus con los mismos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
EP1608411B1 (de) 2003-04-01 2010-09-29 United States Government as represented by the Department of Veteran's Affaires Auf stammzellen, vorläuferzellen oder targetzellen basierende behandlung von multiorganversagen.
US20060084167A1 (en) * 2004-10-16 2006-04-20 Cohenford Menashi A Formation of Hybrid Cells by Fusion of Lineage Committed Cells with Stem Cells
CA2693382C (en) 2006-09-19 2013-09-17 Insugen, Llc Fused stem cells useful for the treatment of diabetes and methods thereof

Also Published As

Publication number Publication date
EP2061874A2 (de) 2009-05-27
DK2061874T3 (da) 2012-05-29
WO2008036349A2 (en) 2008-03-27
CA2693382A1 (en) 2008-03-27
US8372641B2 (en) 2013-02-12
CA2693382C (en) 2013-09-17
US8119120B2 (en) 2012-02-21
EP2061874B1 (de) 2012-02-08
US20100034866A1 (en) 2010-02-11
EP2061874A4 (de) 2010-01-06
WO2008036349A3 (en) 2008-06-26
US20120148551A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
WO2011082038A3 (en) Improved reprogramming compositions
DE602006016468D1 (de) Verfahren zur abgabe von fusionspolypeptid in eine zelle
TW200637574A (en) Treatment method
WO2010124142A3 (en) Cell compositions derived from dedifferentiated reprogrammed cells
WO2007048122A3 (en) Antibody-based therapeutics with enhanced adcc activity
BRPI0819609A2 (pt) Diferenciação de células-tronco embrionárias de ser humano
WO2009149956A3 (en) Fusion protein and use thereof
MX359551B (es) Agentes de union diana contra b7-h1.
NZ606988A (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
DE602005020643D1 (de) Verfahren zur aktivierung von nkt-zellen
NO20092331L (no) LINGO-bindingsmolekyler og farmasoytisk anvendelse derav
TW200740416A (en) Corneal onlays and related methods
DE602005006990D1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
WO2011097181A3 (en) Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
DE602007003331D1 (de) Verfahren zur bestimmung der kopienummer
WO2008088882A3 (en) Methods of generating cardiomyocytes
EP2379577A4 (de) Zusammensetzungen und verfahren zur umprogrammierung von zellen ohne genetische modifikation
WO2010056808A3 (en) Compositions and methods for re-programming and re-differentiating cells
DE602005020638D1 (de) Selektives kultivierungsverfahren und trennverfahren für kleine hepatozyten mit verwendung von hyaluronsäure
ATE533838T1 (de) Verfahren zur verbesserten einführung von dna in bakterienzellen
TW200722090A (en) Compounds useful for inhibiting chk1
DE602006010400D1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
MX2015014892A (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
ATE414277T1 (de) Verfahren zur verhinderung der zeitabhängigen rna-expression in biologischen zellen